Mga Batayang Estadistika
| CIK | 1682639 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Hyperion DeFi, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 21, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HYPERION DEFI, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Hyperion DeFi, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the corporation is Hyperion DeFi, |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 HYPERION DEFI, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 18, 2025 |
As filed with the Securities and Exchange Commission on August 18, 2025 As filed with the Securities and Exchange Commission on August 18, 2025 Registration No. |
|
| August 18, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 HYPERION DEFI, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share Other 5,672,934 $ 6.455 $ 36,618,788.97 0.0001531 $ 5,606.34 Total Offe |
|
| August 13, 2025 |
Exhibit 99.1 Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results Successfully establishes cryptocurrency treasury reserve focused on the HYPE token and becomes the first publicly listed U.S. company to implement DeFi strategies on Hyperliquid blockchain Accumulates more than 1.5 million HYPE to date and establishes co-branded validator with Kinetiq Reiterates |
|
| August 13, 2025 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.8 Hyperion DeFi, Inc. Amended and Restated Non-Employee Director Compensation Policy Effective as of July 22, 2025 Non-employee members of the board of directors (the “Board”) of Hyperion DeFi, Inc. (the “Company”) shall receive cash and equity compensation for their service on the Board as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 HYPERION DEFI, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 HYPERION DEFI, INC. |
|
| July 24, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only |
|
| July 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Hyperion DeFi, Inc. |
|
| July 18, 2025 |
As filed with the Securities and Exchange Commission on July 18, 2025 As filed with the Securities and Exchange Commission on July 18, 2025 Registration No: 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| July 7, 2025 |
Up to $23,295,524 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-282458 Prospectus Supplement (To Prospectus Supplements Dated June 27, 2025, June 2, 2025, April 17, 2025 and December 30, 2024 To Prospectus dated October 8, 2024) Up to $23,295,524 of Common Stock This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus dated October 8, 2024 (the “Prior Pro |
|
| July 2, 2025 |
Separation and Release Agreement by and between the Company and Bren Kern, dated July 1, 2025 Exhibit 10.1 Date: July 1, 2025 Bren Kern 5280 Old Midland Rd. Klamath Falls, OR 97603 Re: Separation and Release Agreement Dear Bren: As we discussed, your employment with Hyperion Defi, Inc. (the “Company”) is terminated effective July 1, 2025 (the “Termination Date”). Your final paycheck will be delivered to you via direct deposit on the Termination Date. The enclosed Separa |
|
| July 2, 2025 |
Exhibit 99.1 Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. Name change reflects company’s leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol “HYPD” effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, CA, July 2, 2025 – |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 HYPERION DEFI, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File |
|
| July 2, 2025 |
Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EYENOVIA, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Eyenovia, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is Eyenovia, Inc. 2. The Cor |
|
| June 27, 2025 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 27, 2025 |
Up to $14,942,887 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-282458 Prospectus Supplement (To Prospectus Supplements Dated June 2, 2025, April 17, 2025 and December 30, 2024 To Prospectus dated October 8, 2024) Up to $14,942,887 of Common Stock This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus dated October 8, 2024 (the “Prior Prospectus”), file |
|
| June 27, 2025 |
Exhibit 99.1 Eyenovia Announces Co-Branded Validator with Kinetiq Kinetiq x Hyperion provides a premier liquid staking solution for institutional HYPE holders LAGUNA HILLS, CA, June 25, 2025 – Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyp |
|
| June 24, 2025 |
Executive Employment Agreement by and between Eyenovia, Inc. and Hyunsu Jung, dated June 17, 2025 Exhibit 10.4 Certain information in this Exhibit was omitted by means of marking such information with brackets (“[***]”) because the identified information (i) is not material and (ii) is the type of information that the Company treats as private or confidential. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the "Agreement') is entered as of June 17, 2025 by and between Eyenovia, Inc., a Delawa |
|
| June 24, 2025 |
Form of Placement Agent Warrant, dated June 17, 2025 Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT F |
|
| June 24, 2025 |
Form of Securities Purchase Agreement, dated June 17, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 17, 2025, is by and between Eyenovia, Inc., a Delaware corporation (the “Company”), and each investor identified in the signature pages hereto (each, including its successors and assigns, an “Investor” and together the “Investors” and, together with the Company, the “Parties” and each |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 24, 2025 |
Form of Lender Warrant, dated June 17, 2025 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 24, 2025 |
Exhibit 10.3 FOURTH AMENDMENT TO SUPPLEMENT TO LOAN AND SECURITY AGREEMENT This Fourth Amendment to Supplement to Loan and Security Agreement (this “Amendment”) is entered into as of June 17, 2025, by and among AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative and collateral agent (in such capacity, “Agent”)), AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware |
|
| June 24, 2025 |
Exhibit 10.5 Certain information in this Exhibit was omitted by means of marking such information with brackets (“[***]”) because the identified information (i) is not material and (ii) is the type of information that the Company treats as private or confidential. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the "Agreement') is entered into effective as |
|
| June 24, 2025 |
EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy Exhibit 99.2 Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group June 18, 2025 at 8:32 AM EDT EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) - Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer |
|
| June 24, 2025 |
Exhibit 99.1 Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy June 17, 2025 at 2:55 PM EDT Announces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed Chief Investment Officer and Board Member LAGUNA HILLS, Calif., June 17, 2025 (GLOBE NEWSWIRE) - Eyenov |
|
| June 24, 2025 |
Form of Purchaser Warrant, dated June 17, 2025 Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT F |
|
| June 24, 2025 |
Form of Registration Rights Agreement, dated June 17, 2025 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 17, 2025, is by and among Eyenovia, Inc., a Delaware corporation (the “Company”), and each investor signatory hereto (each, a “Holder” and collectively, together with its respective permitted assigns, the “Holders”). RECITALS A. In connection with the Securities Purchase Agr |
|
| June 24, 2025 |
Certificate of Designation of Series A Non-Voting Convertible Preferred Stock Exhibit 3.1 Eyenovia, Inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES a NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Eyenovia, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Board of Dir |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 5, 2025 |
Exhibit 10.1 THIRD AMENDMENT TO SUPPLEMENT TO LOAN AND SECURITY AGREEMENT This Third Amendment to Supplement to Loan and Security Agreement (this “Amendment”) is entered into as of May 30, 2025, by and among AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative and collateral agent (in such capacity, “Agent”)), AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware lim |
|
| June 2, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-282458 Prospectus Supplement (To Prospectus Supplements Dated April 17, 2025 and December 30, 2024 To Prospectus dated October 8, 2024) Up to $857,500 of Common Stock This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus, dated October 8, 2024 (the “Prior Prospectus”), filed with the Secur |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| May 19, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 19, 2025 |
Exhibit 99.1 Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and remains o |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: March 31, 2025 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Perio |
|
| May 2, 2025 |
Letter from Marcum LLP, dated May 2, 2025, addressed to the Securities and Exchange Commission Exhibit 16.1 May 2, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Eyenovia, Inc. under Item 4.01 of its Form 8-K dated May 2, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Eyenovia, Inc. contained therein. Very truly |
|
| May 2, 2025 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. |
|
| April 25, 2025 |
Up to 6,370,387 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-286617 PROSPECTUS Up to 6,370,387 Shares of Common Stock This prospectus relates to the offer and sale from time to time, by the selling securityholders identified in this prospectus, of up to 6,370,387 shares of the common stock, par value $0.0001 per share (the “Common Stock”), of Eyenovia, Inc. (the “Company”) which includes (i) up to 23,771 |
|
| April 24, 2025 |
April 24, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Eyenovia, Inc. (the “Company”) Registration Statement Filed on Form S-3 (the “Registration Statement”) File No. 333-286617 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respe |
|
| April 18, 2025 |
As filed with the Securities and Exchange Commission on April 17, 2025 As filed with the Securities and Exchange Commission on April 17, 2025 Registration No: 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Eyenovia, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry-Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Typ |
|
| April 17, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-282458 Prospectus Supplement (To Prospectus dated October 8, 2024) Up to $1,816,756 We previously entered into an amended and restated sales agreement (the “Sales Agreement”) with Chardan Capital Markets, LLC (“Chardan”), dated as of December 30, 2024, relating to the offer and sale of shares of our common stock, $0.0001 par value per share, ha |
|
| April 15, 2025 |
Amendment No. 1 to Warrant Issued on November 26, 2024, dated December 9, 2024 Exhibit 4.9 AMENDMENT No. 1 TO COMMON Stock PURCHASE WARRANT THIS AMENDMENT NO. 1 TO COMMON stock PURCHASE WARRANT (this “Amendment”) is entered into as of December [ ], 2024, by and between Eyenovia, Inc., a Delaware corporation (the “Company”), and Armistice Capital Master Fund Ltd. (the “Holder”). WHEREAS, the Holder is the holder of that certain common stock purchase warrant issued by the Comp |
|
| April 15, 2025 |
Amendment No. 1 to Warrant Issued on September 30, 2024, dated December 9, 2024 Exhibit 4.7 AMENDMENT No. 1 TO COMMON Stock PURCHASE WARRANT THIS AMENDMENT NO. 1 TO COMMON stock PURCHASE WARRANT (this “Amendment”) is entered into as of December [ ], 2024, by and between Eyenovia, Inc., a Delaware corporation (the “Company”), and Armistice Capital Master Fund Ltd. (the “Holder”). WHEREAS, the Holder is the holder of that certain common stock purchase warrant issued by the Comp |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| April 15, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Eyenovia, Inc. (“we”, “our” and “us”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.0001 par value per share. The following summary of our common stock does not pur |
|
| April 15, 2025 |
Exhibit 19.1 INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Company Securities This Policy provides guidelines to employees, officers, directors and consultants of Eyenovia, Inc. and any subsidiaries (the “Company”) with respect to transactions in the Company’s securities and the disclosure of material nonpublic information regarding the Company. Applicability of Pol |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Pe |
|
| March 20, 2025 |
Exhibit 99.1 Eyenovia Enters into Non-Binding Letter of Intent to effect Reverse Merger with Betaliq Combination, if successful, would be a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue marketing Eyenovia’s FDA-approved products – and plans to in-license |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Eyenovia, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par va |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 24, 2025 |
Exhibit 10.1 SECOND AMENDMENT TO SUPPLEMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Supplement to Loan and Security Agreement (this “Amendment”) is entered into as of February 21, 2025, by and among AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative and collateral agent (in such capacity, “Agent”)), AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaw |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 31, 2025 |
Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EYENOVIA, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Eyenovia, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is Eyenovia, Inc. 2. The Thi |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 28, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 28, 2025 |
Exhibit 99.1 Eyenovia Announces 1-for-80 Reverse Stock Split Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives NEW YORK, January 28, 2025 – Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing |
|
| January 24, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 16, 2025 |
Form of Series B Warrant Issued on January 17, 2025 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 16, 2025 |
Form of Series A Warrant Issued on January 17, 2025 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 16, 2025 |
Up to 15,769,445 Shares of Common Stock Underlying Warrants to Purchase Shares of Common Stock 424B3 1 tm253514d2424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-282458 PROSPECTUS SUPPLEMENT (To Prospectus dated October 8, 2024) Up to 15,769,445 Shares of Common Stock Underlying Warrants to Purchase Shares of Common Stock This prospectus supplement, dated January 16, 2025 (the “Supplement”), filed by Eyenovia, Inc. (the “Company”), modifies and supplements certain inf |
|
| January 16, 2025 |
Inducement Letter, dated January 16, 2025 Exhibit 10.1 EYENOVIA, INC. 295 Madison Avenue, Suite 2400 New York, NY 10017 January 16, 2025 To the Holders of March 2022 Common Stock Purchase Warrants, August 2023 Common Stock Purchase Warrants and July 2024 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: EYENOVIA, INC. (the “Company”) is pleased to offer (this “Inducement O |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission |
|
| December 30, 2024 |
Up to $33,586,557 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-282458 PROSPECTUS SUPPLEMENT (To Prospectus dated October 8, 2024) Up to $33,586,557 Common Stock We have entered into an amended and restated sales agreement (the “Sales Agreement”) with Chardan Capital Markets, LLC (“Chardan”), dated as of December 30, 2024, relating to the sale of shares of our common stock, $0.0001 par value per share, offe |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 30, 2024 |
Exhibit 1.1 Execution Version EYENOVIA, INC. Shares of Common Stock ($0.0001 par value per share) AMENDED AND RESTATED SALES AGREEMENT December 30, 2024 CHARDAN CAPITAL MARKETS, LLC One Pennsylvania Avenue, Suite 4800 New York, New York 10119 Ladies and Gentlemen: Eyenovia, Inc., a Delaware corporation (the “Company”), together with Leerink Partners LLC (“Leerink Partners”) are parties to that cer |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 9, 2024 |
Form of Warrant Issued on December 9, 2024 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT EYENOVIA, INC. Warrant Shares: 40,170,050 Issue Date: December 9, 2024 Initial Exercise Date: Stockholder Approval Date THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condit |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 9, 2024 |
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering Exhibit 99.1 Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering December 6, 2024 at 8:00 AM EST NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) - Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today a |
|
| December 9, 2024 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT EYENOVIA, INC. Warrant Shares: 9,085,025 Issue Date: December 9, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a |
|
| December 9, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-282458 PROSPECTUS SUPPLEMENT (To Prospectus dated October 8, 2024) 11,000,000 Shares of Common Stock Warrants to Purchase Up to 40,170,050 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 9,085,025 Shares of Common Stock We are offering directly to a certain institutional investor 11,000,000 shares (the “Shares”) of our common stock |
|
| December 9, 2024 |
Form of Securities Purchase Agreement, dated December 5, 2024. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 5, 2024, between Eyenovia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo |
|
| December 4, 2024 |
EYEN / Eyenovia, Inc. / Grant Stuart M. - AMENDMENT NO.6 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 6) Under the Securities Exchange Act of 1934 Eyenovia, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 30234E 104 (CUSIP Number) Stuart M. Grant 11 Summit Lane Greenville, DE 19807 302 449-4300 (Name, Address and Telephone Number of Person Authorized |
|
| November 26, 2024 |
Form of Warrant Issued on November 26, 2024 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT EYENOVIA, INC. Warrant Shares: Issue Date: November [●], 2024 Initial Exercise Date: May [●], 2025 THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time beginning on May |
|
| November 26, 2024 |
Form of Securities Purchase Agreement, dated November 24, 2024. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 24, 2024, between Eyenovia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set f |
|
| November 26, 2024 |
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering Exhibit 99.1 Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) - Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered int |
|
| November 26, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-282458 PROSPECTUS SUPPLEMENT (To Prospectus dated October 8, 2024) 9,000,000 Shares of Common Stock Warrants to Purchase Up to 24,163,570 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 3,081,785 Shares of Common Stock We are offering directly to a certain institutional investor 9,000,000 shares (the “Shares”) of our common stock, |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 26, 2024 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT EYENOVIA, INC. Warrant Shares: Issue Date: November [·], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any tim |
|
| November 25, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO SUPPLEMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Supplement to Loan and Security Agreement (this “Amendment”) is entered into as of November 22, 2024, by and among AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative and collateral agent (in such capacity, “Agent”)), AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delawar |
|
| November 25, 2024 |
Exhibit 10.2 SUBSCRIPTION AGREEMENT Eyenovia, Inc. 295 Madison Avenue, Suite 2400 New York, NY 10017 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and among Eyenovia, Inc., a Delaware corporation (the “Company”), Avenue Venture Opportunities Fund, L.P. (“Avenue”) and Avenue Venture O |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 15, 2024 |
Exhibit 99.1 Eyenovia Provides Update on Phase 3 CHAPERONE Study A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and evaluate next steps for the program NEW YORK— November 15, 2024—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today anno |
|
| November 14, 2024 |
EYEN / Eyenovia, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-eyen093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* EYENOVIA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30234E104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| November 13, 2024 |
As filed with the Securities and Exchange Commission on November 12, 2024 As filed with the Securities and Exchange Commission on November 12, 2024 Registration No. |
|
| November 13, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Eyenovia, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per s |
|
| November 12, 2024 |
Form of Notice of Inducement Stock Option Grant Exhibit 10.7 EYENOVIA, INC. NOTICE OF INDUCEMENT STOCK OPTION GRANT (Grantee name and address) You have been granted an option to purchase shares of the Common Stock of Eyenovia, Inc. as follows, subject to the terms and conditions of the attached Inducement Stock Option Award Agreement. Capitalized terms used but not defined in this Notice of Inducement Stock Option Grant have the meanings set fo |
|
| November 12, 2024 |
Form of Indemnification and Advancement Agreement Exhibit 10.8 INDEMNIFICATION AND ADVANCEMENT AGREEMENT This Indemnification and Advancement Agreement (“Agreement”) is made as of , 2024 by and between Eyenovia, Inc., a Delaware corporation (the “Company”), and [name], [a member of the Board of Directors/an officer/an employee/an agent] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between t |
|
| November 12, 2024 |
Exhibit 99.1 Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its second generation Optejet device Announced the U.S. launch and commercial availability of |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| October 4, 2024 |
October 4, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Eyenovia, Inc. (the “Company”) Registration Statement Filed on Form S-3 (the “Registration Statement”) File No. 333-282458 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respe |
|
| October 1, 2024 |
Exhibit 4.1 EYENOVIA, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 3 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series. 4 Section 2.2. Establishment of T |
|
| October 1, 2024 |
As filed with the Securities and Exchange Commission on October 1, 2024 As filed with the Securities and Exchange Commission on October 1, 2024 Registration No: 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Eyenovia, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee |
|
| September 30, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-261638 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) 8,630,000 Shares of Common Stock Warrants to Purchase Up to 8,695,653 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 65,653 Shares of Common Stock We are offering directly to a certain purchaser 8,630,000 shares (the “Shares”) of our com |
|
| September 30, 2024 |
Form of Warrant Issued on September 30, 2024 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT EYENOVIA, INC. Warrant Shares: 8,695,653 Initial Exercise Date: March 31, 2025 Issue Date: September 30, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time beginn |
|
| September 30, 2024 |
Form of Securities Purchase Agreement, dated September 26, 2024. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 26, 2024, between Eyenovia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| September 30, 2024 |
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering Exhibit 99.1 Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) - Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purcha |
|
| September 30, 2024 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT EYENOVIA, INC. Warrant Shares: 65,653 Issue Date: September 30, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time beginning on September 30 |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File |
|
| September 3, 2024 |
Exhibit 99.1 Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition NEW YORK— September 3, 2024—Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in p |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 3, 2024 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and effective this 30th day of August 2024 (the “Effective Date”), by and between Eyenovia, Inc., a Delaware corporation (the “Company”), and Andrew D. Jones, an individual resident of California (“Executive”). The Company and Executive are herein referred to each as a “Party” and together |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 23, 2024 |
Exhibit 99.1 August 2024 Our Vision is to Improve Yours With topical ophthalmic therapies that are easier to use and easier to live with EYEN-COM-V2-0021 Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements t |
|
| August 22, 2024 |
Form of Securities Purchase Agreement, dated August 21, 2024 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 21, 2024, between Eyenovia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 22, 2024 |
Eyenovia Announces Pricing of $5.14 Million Public Offering Exhibit 99.2 Eyenovia Announces Pricing of $5.14 Million Public Offering August 21, 2024 NEW YORK, August 21, 2024 (GLOBE NEWSWIRE) – Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering"). The closing of the Offering is expected t |
|
| August 22, 2024 |
Eyenovia, Inc. Announces Proposed Public Offering Exhibit 99.1 Eyenovia, Inc. Announces Proposed Public Offering NEW YORK, August 20, 2024 (GLOBE NEWSWIRE) – Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof) in a best efforts offering. All of the securities to be sold in the offeri |
|
| August 21, 2024 |
Subject to Completion Preliminary Prospectus Supplement dated August 20, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| August 21, 2024 |
12,850,000 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-261638 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) 12,850,000 Shares of Common Stock We are offering directly to certain purchasers 12,850,000 shares of our common stock, par value $0.0001 per share (the “Common Stock”) at a price of $0.40 per share for an aggregate purchase price of $5,140,000. The Commo |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| August 13, 2024 |
Exhibit 99.1 Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for analysis in Q4 Commenced sales activi |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 18, 2024 |
EYEN / Eyenovia, Inc. / Ianchulev Tsontcho - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Eyenovia, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 30234E 104 (CUSIP Number) Tsontcho Ianchulev 295 Madison Avenue, Suite 2400 New York, NY 10017 917-289-1117 (Name, Address and Telephone Number of Person Autho |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 1, 2024 |
Form of Securities Purchase Agreement, dated June 27, 2024 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 27, 2024, between Eyenovia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| July 1, 2024 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT EYENOVIA, INC. Warrant Shares: [] Initial Exercise Date: January 1, 2025 Issue Date: July 1, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time beginning on Janua |
|
| July 1, 2024 |
Warrant Amendment Agreement, dated June 27, 2024 Exhibit 10.2 June 27, 2024 Holder of Warrants to Purchase Common Stock Re: Amendment to Existing Warrants Dear [***] (the “Holder”): This letter confirms that Eyenovia, Inc., a Delaware corporation (the “Company”), hereby amends, effective as of the date hereof, the Holder’s existing warrants to purchase up to 9,708,839 shares of the Company’s common stock, par value $0.0001 per share (“Common Sto |
|
| July 1, 2024 |
Warrant Amendment Agreement, dated June 28, 2024 Exhibit 10.3 June 28, 2024 Holder of Warrants to Purchase Common Stock Issued on March 24, 2020 Re: Amendment to Existing Warrants Dear [***] (the “Holder”): This letter confirms that Eyenovia, Inc., a Delaware corporation (the “Company”), hereby amends, effective as of the date hereof, the Holder’s existing warrants to purchase up to 677,430 shares of the Company’s common stock, par value $0.0001 |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 1, 2024 |
Warrants to Purchase 9,708,839 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-261638 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) Warrants to Purchase 9,708,839 Shares of Common Stock This prospectus supplement, dated July 1, 2024 (the “Supplement”), filed by Eyenovia, Inc. (the “Company”), modifies and supplements certain information contained in (i) the Company’s prospectus supplement, dated March 4, 2 |
|
| July 1, 2024 |
Eyenovia Announces Pricing of $5M Registered Direct Offering Exhibit 99.1 Eyenovia Announces Pricing of $5M Registered Direct Offering NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) – Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current largest stockholder, providing for the purchase and sale of 7,5 |
|
| June 28, 2024 |
7,575,757 Shares of Common Stock Warrants to Purchase Up to 9,325,537 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-261638 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) 7,575,757 Shares of Common Stock Warrants to Purchase Up to 9,325,537 Shares of Common Stock We are offering directly to certain purchasers 7,575,757 shares (the “Shares”) of our common stock, par value $0.0001 per share (the “Common Stock”) and warrants to |
|
| June 14, 2024 |
Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EYENOVIA, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Eyenovia, Inc. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify that: 1. The n |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 4, 2024 |
Exhibit 99.1 June 2024 We Are the Optejet® Company Developing and commercializing ophthalmic therapeutics with Optecare Ρ services in large markets with high unmet needs EYEN - COM - V2 - 0021 Forward - looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forwar d - l ooking statements. Forward - looking statement |
|
| May 16, 2024 |
Up to $10,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-261638 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) Up to $10,000,000 Common Stock We have entered into an open market sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), dated as of December 14, 2021, relating to the sale of shares of our common stock, $0.0001 par value per share, offered by |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| May 15, 2024 |
Exhibit 10.1 [Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified portions are both not material and the type that the registrant treats as private or confidential.] January 12, 2024 CONFIDENTIAL VIA EMAIL AND COURIER [***] Bausch and Lomb 3013 Lake Drive Citywest Busines |
|
| May 15, 2024 |
Exhibit 99.1 Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine Preparing for a 3Q 2024 launch of the first new o |
|
| May 3, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. |
|
| April 23, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 10, 2024 |
3,223,726 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-261638 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) 3,223,726 Shares of Common Stock We are offering directly to certain purchasers 3,223,726 shares of our common stock, par value $0.0001 per share (the “Common Stock”) at a price of $0.6204 per share for an aggregate purchase price of $2,000,000. The Common |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 9, 2024 |
Form of Securities Purchase Agreement, dated April 8, 2024. Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 8, 2024, between Eyenovia, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 19, 2024 |
Exhibit 99.1 March 2024 We Are the Optejet® Company Developing and commercializing ophthalmic therapeutics with Optecare services in large markets with high unmet needs EYEN-COM-V2-0021 Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 18, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97.1 Eyenovia, Inc. Compensation Clawback Policy Adopted October 4, 2023 Purpose The Board of Directors (the “Board”) of Eyenovia, Inc. (the “Corporation”) has adopted this compensation clawback policy (the “Policy”) which provides for the recoupment of incentive-based compensation in the event of an accounting restatement. This Policy is intended to comply with Section 10D of the Securiti |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| March 18, 2024 |
Exhibit 10.38 [Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified portions are both not material and the type that the registrant treats as private or confidential.] January 12, 2024 CONFIDENTIAL VIA EMAIL AND COURIER [***] Bausch and Lomb 3013 Lake Drive Citywest Busine |
|
| February 14, 2024 |
EYEN / Eyenovia, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-eyen123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EYENOVIA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 30234E104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) |
|
| January 31, 2024 |
Exhibit 99.1 January 2024 We Are the Optejet® Company Developing and commercializing ophthalmic drug - device therapeutics with Optecare Ρ services in large markets with high unmet needs EYEN - COM - V2 - 0021 Forward - looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forwar d - l ooking statements. Forward - |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 25, 2024 |
Eyenovia, Inc. Updated Corporate Presentation, dated January 2024 Exhibit 99.1 |
|
| January 16, 2024 |
Exhibit 99.1 Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007 Part of corporate strategy to expedite commercialization of advanced products using the Optejet device Market es |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 13, 2023 |
Exhibit 10.1 Execution Version Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[***]”) because the identified confidential portions (i) are not material and (ii) contain the type of information that the registrant treats as private or confidential. LICENSE AGREEMENT dated August 15, 2023 by and between FORMOSA PHARMACEUTICALS, INC. and E |
|
| November 13, 2023 |
Exhibit 99.1 Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals Announced FDA approval of Coastline International as contract manufacturer for Mydcombi cartridge subassemblies and preparations for national launch Compan |
|
| November 13, 2023 |
Exhibit 99.2 November 2023 FOCUS: INCREASING VALUE NOW AND IN THE FUTURE Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any |
|
| September 20, 2023 |
Exhibit 99.1 September 2023 EYEN-COM-V2-0012 1 Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File |
|
| August 30, 2023 |
Warrants to Purchase 4,870,130 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-261638 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) Warrants to Purchase 4,870,130 Shares of Common Stock This prospectus supplement, dated August 29, 2023 (the “Supplement”), filed by Eyenovia, Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus supplement, dated March 7, |
|
| August 29, 2023 |
Form of Warrant issued on August 29, 2023 Exhibit 4.2 PREFUNDED COMMON STOCK PURCHASE WARRANT EYENOVIA, INC. Warrant Shares: 2,252,979 Issue Date: August 29, 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| August 29, 2023 |
Form of Warrant Issued on August 29, 2023 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT EYENOVIA, INC. Warrant Shares: 4,838,709 Issue Date: August 29, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time beginning on March 1, 2024 (the “Initial Exerci |
|
| August 29, 2023 |
EYENOVIA ANNOUNCES $12 MILLION REGISTERED DIRECT OFFERING Exhibit 99.1 EYENOVIA ANNOUNCES $12 MILLION REGISTERED DIRECT OFFERING NEW YORK, August 24, 2023 (GLOBE NEWSWIRE) - Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates f |
|
| August 29, 2023 |
Securities Purchase Agreement, dated August 24, 2023 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 24, 2023, between Eyenovia, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an |
|
| August 29, 2023 |
Warrant Amendment Agreement, dated August 24, 2023 Exhibit 10.2 August 24, 2023 Holder of Warrants to Purchase Common Stock Issued on March 7, 2022 Re: Amendment to Existing Warrants Dear [***] (the “Holder”): This letter confirms that Eyenovia, Inc., a Delaware corporation (the “Company”), hereby amends, effective as of the date hereof, the Holder’s existing warrants to purchase up to 4,870,130 shares of the Company’s common stock, par value $0.0 |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 25, 2023 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-261638 PROSPECTUS SUPPLEMENT (To Prospectus dated December 23, 2021) 4,198,633 Shares of Common Stock Warrants to Purchase Up to 4,838,709 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,252,979 Shares of Common Stock We are offering 4,198,633 shares of our common stock (the “Shares”), par value $0.0001 per sh |
|
| August 16, 2023 |
Boldly Go Where Eyecare H a s Never Gone Before August 2023 Exhibit 99.2 Boldly Go Where Eyecare H a s Never Gone Before August 2023 Forward looking statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forwar d - looking statements. Forward - looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions o |
|
| August 16, 2023 |
Exhibit 99.1 Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery Further leverages Eyenovia’s Mydcombi sales force and represents additional near-te |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 10, 2023 |
Exhibit 99.1 Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update Announced FDA approval of and first commercial sale of Mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first FDA approved product to utilize the Optejet® Continued to advance its Phase 3 Apersure™ (Microline) presbyopia candidate following receipt of gu |
|
| June 27, 2023 |
Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan, as Amended Exhibit 10.1 EYENOVIA, INC. AMENDED AND RESTATED 2018 OMNIBUS STOCK INCENTIVE PLAN, AS AMENDED 2018 Omnibus Stock Incentive Plan Approved by the Board and Stockholders on March 6, 2018 and June 11, 2018, respectively Amendment to 2018 Omnibus Stock Incentive Plan Approved by the Board and Stockholders on April 5, 2019 and June 11, 2019, respectively Amendment and Restatement of 2018 Omnibus Stock |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 27, 2023 |
Exhibit 99.1 2023 Annual Meeting 1 Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our futu |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 27, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Eyenovia, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0 |
|
| June 27, 2023 |
As filed with the Securities and Exchange Commission on June 27, 2023 As filed with the Securities and Exchange Commission on June 27, 2023 Registration No. |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| May 11, 2023 |
Exhibit 99.2 May 2023 1 Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activiti |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement. ¨ Confidential, for Use of the Commission Only (as permitted by R |
|
| May 11, 2023 |
Exhibit 99.1 Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet® Received feedback from FDA on its Phase 3 Microline presbyopia candidate that provides a clear and efficient path forward for the program E |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 11, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only |
|
| May 8, 2023 |
Exhibit 99.1 Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis Provides critical validation of key technology that is core to Eyenovia’s proprietary development programs as well as current an |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 1, 2023 |
Form of Restricted Stock Unit Agreement Exhibit 10.34 EYENOVIA, INC. AMENDED AND RESTATED 2018 OMNIBUS STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Agreement”) is made and entered into between Eyenovia, Inc. (the “Company”) and (“Grantee”), effective as of [] (the “Date of Grant”). This Agreement sets forth the terms and conditions associated with the Company’s award to Gra |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. |
|
| March 31, 2023 |
Employment Agreement, dated December 19, 2022, by and between Eyenovia, Inc. and Bren Kern Exhibit 10.33 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 19, 2022, by and between Eyenovia, Inc., a Delaware company (the “Company”), and Bren Kern, an individual residing in the State of Oregon (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties,” and individually a “Party.” AGREEMENT 1.Position, Du |
|
| March 31, 2023 |
Exhibit 10.31 SUPPLEMENT to the Loan and Security Agreement dated as of November 22, 2022 between EYENOVIA, INC. (“Borrower”) and AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership, as administrative agent and collateral agent (in such capacity “Agent”) and AVENUE VENTURE OPPORTUNITIES FUND, L.P. II, a Delaware limited partnership (“Avenue 2”), as a lender and AVENUE VENTURE OPPORT |
|
| March 31, 2023 |
Exhibit 10.32 SUBSCRIPTION AGREEMENT Eyenovia, Inc. 295 Madison Avenue, Suite 2400 New York, NY 10017 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and among Eyenovia, Inc., a Delaware corporation (the “Company”), Avenue Venture Opportunities Fund, L.P. (“Avenue”) and Avenue Venture |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| March 31, 2023 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Our authorized capital stock consists of 90,000,000 shares of common stock, $0.0001 par value per share, and 6,000,000 shares of undesignated preferred stock, par value $0.0001 per share. The following description summarizes the material terms of our capital stock. Becaus |
|
| March 31, 2023 |
Exhibit 10.30 LOAN AND SECURITY AGREEMENT Dated as of November 22, 2022 between EYENOVIA, INC., a Delaware corporation, as “Borrower”, and AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership, as administrative agent and collateral agent (in such capacity “Agent”) and AVENUE VENTURE OPPORTUNITIES FUND, L.P. II, a Delaware limited partnership (“Avenue 2”), as a lender and AVENUE VENTU |
|
| March 30, 2023 |
Exhibit 99.1 Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining a clear path forward for the program Entered into co-develo |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 30, 2023 |
Exhibit 99.2 March 2023 1 Forward - looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forwar d - l ooking statements. Forward - looking statements include, but are not limited to, statements that express our intentions, beliefs, expecta tions, strategies, predictions or any other statements relating to our futu |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 28, 2023 |
Exhibit 99.1 Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement NEW YORK— February 28, 2023—Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 15, 2023 |
Exhibit 99.1 Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs. NEW YORK— February 15, 2023—Eyenovia, Inc. (NA |
|
| February 15, 2023 |
Formosa – Eyenovia Collaboration Exhibit 99.2 Formosa – Eyenovia Collaboration • Publicly traded (6838.TWO) Taiwanese clinical stage biotechnology company – Market cap $200M – Ophthalmology and oncology (biosimilars) focus • In topical eye care, Formosa’s proprietary nanoparticle formulation technology improves the dissolution and bioavailability of drugs – Drugs used in suspensions and possibly emulsions • Ophthalmic products in |
|
| February 13, 2023 |
EYEN / Eyenovia Inc / ESHELMAN FREDRIC N - SC 13D/A Activist Investment SC 13D/A 1 d463886dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Eyenovia, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 30234E 104 (CUSIP Number) Fred Eshelman Eshelman Ventures, LLC 319 North Third Street, Suite 301 Wilmington, North Carol |
|
| January 30, 2023 |
Making it Possible | February 2023 Exhibit 99.1 Making it Possible | February 2023 eyenovia.com 1 Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward - looking statements. Forward - looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 24, 2023 |
EYEN / Eyenovia Inc / Ianchulev Tsontcho - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Eyenovia, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 30234E 104 (CUSIP Number) Tsontcho Ianchulev 295 Madison Avenue, Suite 2400 New York, NY 10017 917-289-1117 (Name, Address and Telephone Number of Person Autho |
|
| January 24, 2023 |
EX-3 2 tm233924-ex3.htm EXHIBIT 3 Exhibit 3 10b5-1 TRADING PLAN 1 of 7 Brokerage services provided by Fidelity Brokerage Services LLC. Member NYSE, SIPC. Accounts carried by National Financial Services LLC. Member NYSE, SIPC. Please call your advisor for any assistance that you may require with the completion of this 10b5-1 Trading Plan. This Plan is subject to Fidelity review and approval. This P |
|
| December 23, 2022 |
EYENOVIA, INC. 2,875,554 Shares of Common Stock The information in this prospectus is not complete and may be changed without notice. |
|
| December 21, 2022 |
EYENOVIA, INC. 295 Madison Avenue, Suite 2400 New York, New York 10017 EYENOVIA, INC. 295 Madison Avenue, Suite 2400 New York, New York 10017 December 21, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller RE: Eyenovia, Inc. Registration Statement on Form S-3 Filed December 16, 2022 File No. 333- 268832 Acceleration Request Dear Mr. Buchmiller: With respec |
|
| December 16, 2022 |
As filed with the Securities and Exchange Commission on December 16, 2022 As filed with the Securities and Exchange Commission on December 16, 2022 Registration No. |
|
| December 16, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE TABLE Form S-3 (Form Type) Eyenovia, Inc. |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 13, 2022 |
Exhibit 99.1 Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel Optejet® drug delivery technology Company also announced receipt of California Medical Device Manufacturing license NEW YORK—December 13, 2022—Eyenovia, Inc |
|
| December 8, 2022 |
Exhibit 99.1 Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President Company also announces that Julia Haller, MD, is stepping down from its Board of Directors NEW YORK—December 8, 2022—Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device t |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 29, 2022 |
Exhibit 99.1 Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi™ NEW YORK—November 29, 2022—Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use bot |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-38365 EYENOVIA, INC. |
|
| November 14, 2022 |
Non-Employee Director Compensation Policy, as amended Exhibit 10.1 EYENOVIA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective as of April 1, 2022; revised August 1, 2022 Non-employee members of the board of directors (the “Board”) of Eyenovia, Inc. (the “Company”) shall receive cash and equity compensation for their service on the Board as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compens |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 10, 2022 |
Exhibit 99.1 Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/device combination product Company to host conference call and webcast today, November 10, at 4:30 pm ET NEW YORK?No |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 20, 2022 |
Exhibit 99.1 Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia NEW YORK—October 20, 2022—Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric pr |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 EYENOVIA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38365 47-1178401 (State or other jurisdiction of incorporation) (Commission File |
|
| September 30, 2022 |
Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr. Exhibit 99.1 Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr. NEW YORK? September 30, 2022?Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet? delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced the planned retir |
|
| August 12, 2022 |
As filed with the Securities and Exchange Commission on August 12, 2022 As filed with the Securities and Exchange Commission on August 12, 2022 Registration No. |
|
| August 12, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Eyenovia, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock $0.0001 par value per share 457(c) |
|
| August 11, 2022 |
Non-Employee Director Compensation Policy, as amended ? Exhibit 10.4 EYENOVIA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective as of April 1, 2022; revised August 1, 2022 Non-employee members of the board of directors (the ?Board?) of Eyenovia, Inc. (the ?Company?) shall receive cash and equity compensation for their service on the Board as set forth in this Non-Employee Director Compensation Policy (this ?Policy?). The cash and equity compe |
